Seroatlas · Human Serome Atlas

PTPRK

Receptor-type tyrosine-protein phosphatase kappa

Also known as: PTPRK_HUMAN, R-PTP-kappa

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q15262
Gene: PTPRK
Ensembl: ENSG00000152894
Chromosome: 6
Canonical length: 1439 aa
Protein class: Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Vesicles,Plasma membrane,Cell Junctions,Connecting piece,Flagellar centriole

OverviewNCBI Gene

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and two tandem catalytic domains, and thus represents a receptor-type PTP. The extracellular region contains a meprin-A5 antigen-PTP mu (MAM) domain, an Ig-like domain and four fibronectin type III-like repeats. This PTP was shown to mediate homophilic intercellular interaction, possibly through the interaction with beta- and gamma-catenin at adherens junctions. Expression of this gene was found to be stimulated by TGF-beta 1, which may be important for the inhibition of keratinocyte proliferation. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

1439 residues, UniProt reviewed canonical sequence.

>Q15262|PTPRK
     1  MDTTAAAALP AFVALLLLSP WPLLGSAQGQ FSAGGCTFDD GPGACDYHQD LYDDFEWVHV
    61  SAQEPHYLPP EMPQGSYMIV DSSDHDPGEK ARLQLPTMKE NDTHCIDFSY LLYSQKGLNP
   121  GTLNILVRVN KGPLANPIWN VTGFTGRDWL RAELAVSTFW PNEYQVIFEA EVSGGRSGYI
   181  AIDDIQVLSY PCDKSPHFLR LGDVEVNAGQ NATFQCIATG RDAVHNKLWL QRRNGEDIPV
   241  AQTKNINHRR FAASFRLQEV TKTDQDLYRC VTQSERGSGV SNFAQLIVRE PPRPIAPPQL
   301  LGVGPTYLLI QLNANSIIGD GPIILKEVEY RMTSGSWTET HAVNAPTYKL WHLDPDTEYE
   361  IRVLLTRPGE GGTGLPGPPL ITRTKCAEPM RTPKTLKIAE IQARRIAVDW ESLGYNITRC
   421  HTFNVTICYH YFRGHNESKA DCLDMDPKAP QHVVNHLPPY TNVSLKMILT NPEGRKESEE
   481  TIIQTDEDVP GPVPVKSLQG TSFENKIFLN WKEPLDPNGI ITQYEISYSS IRSFDPAVPV
   541  AGPPQTVSNL WNSTHHVFMH LHPGTTYQFF IRASTVKGFG PATAINVTTN ISAPTLPDYE
   601  GVDASLNETA TTITVLLRPA QAKGAPISAY QIVVEELHPH RTKREAGAME CYQVPVTYQN
   661  AMSGGAPYYF AAELPPGNLP EPAPFTVGDN RTYQGFWNPP LAPRKGYNIY FQAMSSVEKE
   721  TKTQCVRIAT KAATEEPEVI PDPAKQTDRV VKIAGISAGI LVFILLLLVV ILIVKKSKLA
   781  KKRKDAMGNT RQEMTHMVNA MDRSYADQST LHAEDPLSIT FMDQHNFSPR YENHSATAES
   841  SRLLDVPRYL CEGTESPYQT GQLHPAIRVA DLLQHINLMK TSDSYGFKEE YESFFEGQSA
   901  SWDVAKKDQN RAKNRYGNII AYDHSRVILQ PVEDDPSSDY INANYIDGYQ RPSHYIATQG
   961  PVHETVYDFW RMIWQEQSAC IVMVTNLVEV GRVKCYKYWP DDTEVYGDFK VTCVEMEPLA
  1021  EYVVRTFTLE RRGYNEIREV KQFHFTGWPD HGVPYHATGL LSFIRRVKLS NPPSAGPIVV
  1081  HCSAGAGRTG CYIVIDIMLD MAEREGVVDI YNCVKALRSR RINMVQTEEQ YIFIHDAILE
  1141  ACLCGETAIP VCEFKAAYFD MIRIDSQTNS SHLKDEFQTL NSVTPRLQAE DCSIACLPRN
  1201  HDKNRFMDML PPDRCLPFLI TIDGESSNYI NAALMDSYRQ PAAFIVTQYP LPNTVKDFWR
  1261  LVYDYGCTSI VMLNEVDLSQ GCPQYWPEEG MLRYGPIQVE CMSCSMDCDV INRIFRICNL
  1321  TRPQEGYLMV QQFQYLGWAS HREVPGSKRS FLKLILQVEK WQEECEEGEG RTIIHCLNGG
  1381  GRSGMFCAIG IVVEMVKRQN VVDVFHAVKT LRNSKPNMVE APEQYRFCYD VALEYLESS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PTPRK can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 31 nTPM

Expression across tissuesHPA

Tissue

duodenum: 31 nTPM
gallbladder: 31 nTPM
stomach: 29 nTPM
liver: 28 nTPM
small intestine: 27 nTPM
rectum: 26 nTPM

Single-cell type

oligodendrocytes: 1,525 nCPM
proximal tubule cells: 622 nCPM
ependymal cells: 555 nCPM
papillary tip epithelial cells: 531 nCPM
renal collecting duct intercalated cells: 519 nCPM
renal collecting duct principal cells: 476 nCPM

Immune cell

naive B-cell: 2.9 nTPM
memory B-cell: 1.6 nTPM
naive CD8 T-cell: 0.4 nTPM
NK-cell: 0.2 nTPM
memory CD8 T-cell: 0.1 nTPM
naive CD4 T-cell: 0.1 nTPM

Brain region

white matter: 53 nTPM
basal ganglia: 35 nTPM
cerebral cortex: 31 nTPM
pons: 30 nTPM
medulla oblongata: 28 nTPM
cerebellum: 27 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.31
gnomAD pLI: 0.9
gnomAD missense Z: 3.17
DepMap mean gene effect: 0.05
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PTPRK in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PTPRK as an antibody target. Whether an autoantibody or antibody against PTPRK could matter depends on whether native PTPRK is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PTPRK is annotated at the cell surface, where native PTPRK is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PTPRK as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...